All 2 tracked stories fall under one category: pharma. AnTenGager is most often covered alongside Antengene Corporation Limited, which appears in 2 of these 2 stories. Across a 173-day span, the pace is roughly 0.1 stories per week. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about AnTenGager
All 2 tracked stories fall under one category: pharma. AnTenGager is most often covered alongside Antengene Corporation Limited, which appears in 2 of these 2 stories. Across a 173-day span, the pace is roughly 0.1 stories per week. Each story carries 2 original sources on average, compared with 3.5 for the broader beat in this window. Their average consequence score of 6 runs below the beat's 6.1 for that window. We currently track 2 Biotech stories that mention AnTenGager, published between March 4, 2026 and August 23, 2026.
Stories tracked
2
Per week
0.1
Sources per story
2
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 632 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering AnTenGager. Shared-story counts are live from our verified record — not editorial picks.
For biotech and pharma professionals, Antengene's showcase demonstrates platform depth in T-cell engager engineering, adding TriGager to its AnTenGager toolbox and introducing a first-in-class αCD3-TGF-β fusion protein. The presentation also included updated ATG-022 data, though no quantitative results were disclosed. This positions Antengene as a company to watch in the crowded CLDN18.2 and TCE arenas.
Antengene has granted UCB exclusive global rights to ATG-201, a CD19/CD3 bispecific T-cell engager, in a deal worth up to $1.18 billion. The partnership leverages Antengene's AnTenGager platform to target B-cell-driven autoimmune diseases, marking a major strategic expansion for both firms.
AnTenGager is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
